Difference between revisions of "Decitabine (Dacogen)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 15: | Line 15: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2012-09-20: Initial authorization | *2012-09-20: Initial authorization | ||
| − | *Uncertain date: Indicated for treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy. | + | *Uncertain date: Indicated for treatment of adult patients with newly diagnosed de novo or secondary [[Acute myeloid leukemia|acute myeloid leukaemia (AML)]], according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy. |
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/decitabine.aspx Decitabine (Dacogen) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/decitabine.aspx Decitabine (Dacogen) patient drug information (Chemocare)]</ref> |
*Patient counseling information can be found in the [https://www.otsuka-us.com/media/static/DACOGEN-PI.pdf Decitabine (Dacogen) package insert]<ref name="insert"></ref> | *Patient counseling information can be found in the [https://www.otsuka-us.com/media/static/DACOGEN-PI.pdf Decitabine (Dacogen) package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/decitabine-patient-drug-information Decitabine (Dacogen) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/decitabine-patient-drug-information Decitabine (Dacogen) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/decitabine-patient-drug-information Decitabine (Dacogen) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/decitabine-patient-drug-information Decitabine (Dacogen) patient drug information (UpToDate)]</ref> | ||
| Line 33: | Line 33: | ||
[[Category:DNA methyltransferase inhibitors]] | [[Category:DNA methyltransferase inhibitors]] | ||
| − | [[Category:Pyrimidine | + | [[Category:Pyrimidine analogs]] |
[[Category:Acute myeloid leukemia medications]] | [[Category:Acute myeloid leukemia medications]] | ||
Latest revision as of 01:02, 29 June 2024
General information
Class/mechanism: Pyrimidine/cytosine analog, DNA hypomethylating agent. Incorporates into DNA and inhibits DNA methyltransferase, causing DNA hypomethylation, which results in cellular differentiation or apoptosis.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication
- 2006-05-02: Initial approval for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. (Based on D-0007)
History of changes in EMA indication
- 2012-09-20: Initial authorization
- Uncertain date: Indicated for treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy.
Patient drug information
- Decitabine (Dacogen) patient drug information (Chemocare)[3]
- Patient counseling information can be found in the Decitabine (Dacogen) package insert[1]
- Decitabine (Dacogen) patient drug information (UpToDate)[4]
Also known as
- Generic name: 5-aza-2'-deoxycytidine
- Brand names: Dacogen, Decima, Decita, Decitafect, Decitas, Decitex, Natdecita